Pevonedistat联合阿扎胞苷对比阿扎胞苷单药治疗高危骨髓增生异常综合征/慢性粒单核细胞白血病或低原始细胞比例急性髓系白血病
PANTHER是一项全球随机3期试验,比较pevonedistat联合阿扎胞苷(n=227)与阿扎胞苷单药(n=227)在新诊断高危骨髓增生异常综合征(MDS;n=324)、高危慢性粒单核细胞白血病(n=27)或原始细胞20%至30%的急性髓系白血病(AML;n=103)患者中的疗效。主要终点为无事件生存期(EFS)。在意向治疗人群中,联合组中位EFS为17.7个月,单药组为15.7个月(HR 0.968;95%CI 0.757-1.238;P=0.557);高危MDS队列中位EFS分别为19.2个月和15.6个月(HR 0.887;95%CI 0.659-1.193;P=0.431)。
要点
- 意向治疗人群联合组中位EFS 17.7个月 vs 单药组15.7个月(HR 0.968;95%CI 0.757-1.238;P=0.557)。
- 高危MDS队列联合组中位EFS 19.2个月 vs 单药组15.6个月(HR 0.887;95%CI 0.659-1.193;P=0.431)。
- 事后分析中,高危MDS队列接受>3个周期者中位OS联合组23.8个月 vs 单药组20.6个月(P=0.021)。
核心结论
- 在意图治疗人群中,pevonedistat联合阿扎胞苷对比阿扎胞苷单药未改善无事件生存期(HR 0.968;95%CI 0.757-1.238;P=0.557)。
- 事后分析显示高危MDS队列接受>3个周期者中位OS联合组23.8个月 vs 单药组20.6个月(P=0.021),接受>6个周期者中位OS联合组27.1个月 vs 单药组22.5个月(P=0.008)。
研究设计与样本
- PANTHER是一项全球随机3期试验,比较pevonedistat联合阿扎胞苷(n=227)与阿扎胞苷单药(n=227)。
- 纳入新诊断高危MDS(n=324)、高危慢性粒单核细胞白血病(n=27)或原始细胞20%至30%的AML(n=103)患者。
- 主要终点为无事件生存期(EFS)。
- 试验注册号:NCT03268954。
主要发现
- 意向治疗人群中位EFS联合组17.7个月 vs 单药组15.7个月(HR 0.968;95%CI 0.757-1.238;P=0.557)。
- 高危MDS队列中位EFS联合组19.2个月 vs 单药组15.6个月(HR 0.887;95%CI 0.659-1.193;P=0.431)。
- 高危MDS队列中位OS联合组21.6个月 vs 单药组17.5个月(HR 0.785;P=0.092)。
- 原始细胞20%至30%的AML患者中位OS联合组14.5个月 vs 单药组14.7个月(HR 1.107;P=0.664)。
- 常见≥3级治疗中出现血液学不良事件:贫血(联合组33% vs 单药组34%)、中性粒细胞减少(联合组31% vs 单药组33%)、血小板减少(联合组30% vs 单药组30%)。
关键数值与推荐
- 未发现新的安全性信号,阿扎胞苷剂量强度得以维持。
- 事后分析:高危MDS队列接受>3个周期者中位OS联合组23.8个月 vs 单药组20.6个月(P=0.021)。
- 事后分析:高危MDS队列接受>6个周期者中位OS联合组27.1个月 vs 单药组22.5个月(P=0.008)。
临床怎么用
- 原文未据此给出推荐。
局限性
- >3个周期和>6个周期的OS分析为事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PANTHER is a global, randomized phase 3 trial of pevonedistat+azacitidine (n = 227) vs azacitidine monotherapy (n = 227) in patients with newly diagnosed higher-risk myelodysplastic syndromes (MDS; n = 324), higher-risk chronic myelomonocytic leukemia (n = 27), or acute myeloid leukemia (AML) with 20% to 30% blasts (n = 103). The primary end point was event-free survival (EFS). In the intent-to-treat population, the median EFS was 17.7 months with pevonedistat+azacitidine vs 15.7 months with azacitidine (hazard ratio [HR], 0.968; 95% confidence interval [CI], 0.757-1.238; P = .557) and in the higher-risk MDS cohort, median EFS was 19.2 vs 15.6 months (HR, 0.887; 95% CI, 0.659-1.193; P = .431). Median overall survival (OS) in the higher-risk MDS cohort was 21.6 vs 17.5 months (HR, 0.785; P = .092), and in patients with AML with 20% to 30% blasts was 14.5 vs 14.7 months (HR, 1.107; P = .664). In a post hoc analysis, median OS in the higher-risk MDS cohort for patients receiving >3 cycles was 23.8 vs 20.6 months (P = .021) and for >6 cycles was 27.1 vs 22.5 months (P = .008). No new safety signals were identified, and the azacitidine dose intensity was maintained. Common hematologic grade ≥3 treatment emergent adverse events were anemia (33% vs 34%), neutropenia (31% vs 33%), and thrombocytopenia (30% vs 30%). These results underscore the importance of large, randomized controlled trials in these heterogeneous myeloid diseases and the value of continuing therapy for >3 cycles. The trial was registered on clinicaltrials.gov as #NCT03268954.
引用
- Adès L, Girshova L, Doronin VA, et al. Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML. Blood Adv. 2022. PMID: 35728048. doi:10.1182/bloodadvances.2022007334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。